Cargando…

Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease

BACKGROUND: Exacerbations are critical events in chronic pulmonary obstructive disease (COPD). The frequency of COPD exacerbations is associated with the prognosis, including mortality, but no useful biomarker has been established. METHODS: The present retrospective study investigated 481 COPD patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Tashiro, Hiroki, Kurihara, Yuki, Takahashi, Koichiro, Sadamatsu, Hironori, Haraguchi, Tetsuro, Tajiri, Ryo, Takamori, Ayako, Kimura, Shinya, Sueoka-Aragane, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720558/
https://www.ncbi.nlm.nih.gov/pubmed/33287777
http://dx.doi.org/10.1186/s12890-020-01362-w
_version_ 1783619874424094720
author Tashiro, Hiroki
Kurihara, Yuki
Takahashi, Koichiro
Sadamatsu, Hironori
Haraguchi, Tetsuro
Tajiri, Ryo
Takamori, Ayako
Kimura, Shinya
Sueoka-Aragane, Naoko
author_facet Tashiro, Hiroki
Kurihara, Yuki
Takahashi, Koichiro
Sadamatsu, Hironori
Haraguchi, Tetsuro
Tajiri, Ryo
Takamori, Ayako
Kimura, Shinya
Sueoka-Aragane, Naoko
author_sort Tashiro, Hiroki
collection PubMed
description BACKGROUND: Exacerbations are critical events in chronic pulmonary obstructive disease (COPD). The frequency of COPD exacerbations is associated with the prognosis, including mortality, but no useful biomarker has been established. METHODS: The present retrospective study investigated 481 COPD patients. Clinical features in the stable period were compared between patients who experienced severe exacerbation (n = 88, 18.3%) and those who never experienced severe exacerbation (n = 393, 81.7%). In the patients who experienced exacerbations, clinical features were also compared between frequent exacerbators (exacerbation rate ≥ 2 times/year, n = 27, 30.7%) and infrequent exacerbators (1 time/year, n = 61, 69.3%). RESULTS: Compared to COPD patients who never experienced exacerbations, body mass index (BMI), serum albumin, and pulmonary functions were significantly lower, and the cardiovascular disease comorbidity rate, COPD assessment test score, modified Medical Research Council dyspnea scale, and use of long-term oxygen therapy, long-acting β(2) adrenergic agonist therapy, inhaled corticosteroid therapy, and macrolide therapy were significantly higher in COPD patients with exacerbations (all p < 0.01). In patients who experienced exacerbations, frequent exacerbators had significantly lower % forced expiratory volume in 1.0 s and a higher risk of critical exacerbations, percentage of blood eosinophils, history of mechanical ventilation use, and use of long-term oxygen therapy and of macrolide therapy than infrequent exacerbators (all p < 0.01). On multivariate analysis, the percentage of blood eosinophils was the parameter most correlated with exacerbation frequency (β value [95% confidence interval] 1.45 [1.12–1.88], p < 0.01). CONCLUSION: Blood eosinophil in the stable period is the factor most correlated with the frequency of severe exacerbations. Trial registration: The patients in this study was registered retrospectively
format Online
Article
Text
id pubmed-7720558
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77205582020-12-07 Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease Tashiro, Hiroki Kurihara, Yuki Takahashi, Koichiro Sadamatsu, Hironori Haraguchi, Tetsuro Tajiri, Ryo Takamori, Ayako Kimura, Shinya Sueoka-Aragane, Naoko BMC Pulm Med Research Article BACKGROUND: Exacerbations are critical events in chronic pulmonary obstructive disease (COPD). The frequency of COPD exacerbations is associated with the prognosis, including mortality, but no useful biomarker has been established. METHODS: The present retrospective study investigated 481 COPD patients. Clinical features in the stable period were compared between patients who experienced severe exacerbation (n = 88, 18.3%) and those who never experienced severe exacerbation (n = 393, 81.7%). In the patients who experienced exacerbations, clinical features were also compared between frequent exacerbators (exacerbation rate ≥ 2 times/year, n = 27, 30.7%) and infrequent exacerbators (1 time/year, n = 61, 69.3%). RESULTS: Compared to COPD patients who never experienced exacerbations, body mass index (BMI), serum albumin, and pulmonary functions were significantly lower, and the cardiovascular disease comorbidity rate, COPD assessment test score, modified Medical Research Council dyspnea scale, and use of long-term oxygen therapy, long-acting β(2) adrenergic agonist therapy, inhaled corticosteroid therapy, and macrolide therapy were significantly higher in COPD patients with exacerbations (all p < 0.01). In patients who experienced exacerbations, frequent exacerbators had significantly lower % forced expiratory volume in 1.0 s and a higher risk of critical exacerbations, percentage of blood eosinophils, history of mechanical ventilation use, and use of long-term oxygen therapy and of macrolide therapy than infrequent exacerbators (all p < 0.01). On multivariate analysis, the percentage of blood eosinophils was the parameter most correlated with exacerbation frequency (β value [95% confidence interval] 1.45 [1.12–1.88], p < 0.01). CONCLUSION: Blood eosinophil in the stable period is the factor most correlated with the frequency of severe exacerbations. Trial registration: The patients in this study was registered retrospectively BioMed Central 2020-12-07 /pmc/articles/PMC7720558/ /pubmed/33287777 http://dx.doi.org/10.1186/s12890-020-01362-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Tashiro, Hiroki
Kurihara, Yuki
Takahashi, Koichiro
Sadamatsu, Hironori
Haraguchi, Tetsuro
Tajiri, Ryo
Takamori, Ayako
Kimura, Shinya
Sueoka-Aragane, Naoko
Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title_full Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title_fullStr Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title_full_unstemmed Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title_short Clinical features of Japanese patients with exacerbations of chronic obstructive pulmonary disease
title_sort clinical features of japanese patients with exacerbations of chronic obstructive pulmonary disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7720558/
https://www.ncbi.nlm.nih.gov/pubmed/33287777
http://dx.doi.org/10.1186/s12890-020-01362-w
work_keys_str_mv AT tashirohiroki clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT kuriharayuki clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT takahashikoichiro clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT sadamatsuhironori clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT haraguchitetsuro clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT tajiriryo clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT takamoriayako clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT kimurashinya clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease
AT sueokaaraganenaoko clinicalfeaturesofjapanesepatientswithexacerbationsofchronicobstructivepulmonarydisease